Canada markets closed

Qiagen N.V. (QIA.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
39.63+0.29 (+0.75%)
At close: 05:35PM CET
Full screen
Previous Close39.34
Open39.37
Bid39.64 x 48300
Ask39.65 x 51100
Day's Range39.18 - 39.74
52 Week Range33.75 - 44.81
Volume793,524
Avg. Volume623,161
Market Cap8.801B
Beta (5Y Monthly)0.41
PE Ratio (TTM)28.11
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.18 (2.94%)
Ex-Dividend DateJan 30, 2024
1y Target EstN/A
  • GlobeNewswire

    QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system

    QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management // Growing global presence: Over 4,000 QIAstat-Dx instruments for reliable, fast and cost‑effective diagnosis of complex syndromes placed worldwide by the end of 2023Venlo, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: Q

  • GlobeNewswire

    QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

    Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers // Updated U.S. CDC guidelines mandate IGRA testing for individuals aged 2 and older from high‑TB incidence countries, as part of U.S. immigrant visa medical exam // QIAGEN to host global, CPD-accredited event on March 21, just before World TB Day, focusing on TB infection screening, preventive therapy and challenges of high-risk groupsGermantown, Maryland, and Venlo, the Netherlands,

  • GlobeNewswire

    QIAGEN announces Form 20-F annual report filing for 2023 results

    Venlo, the Netherlands, March 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will provide printed copies of the 2023 Annual Report to shareholders free of charge upon request. To obtain a p